Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
Abstract Background Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we describe a rare case of a patient with mCRPC who was treated with CBZ che...
Main Authors: | Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5782-2 |
Similar Items
-
Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
by: Yoshinori Yanai, et al.
Published: (2019-07-01) -
Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01) -
Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01) -
Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)